• Biofilm removal by the microfluid jet leads to bacterial load reduction which is important for the healing process
• Stimulation of the wound bed with the microfluid jet increases cellular activity and circulation, which allows the oxygen provided during the treatment to be delivered to the wound
• Provokes microbleeding, which feeds the wound with the oxygen and nutrients needed for neovascularization and tissue growth
• Clinical results show a significantly faster wound healing, a reduced infection rate and fewer adverse events

medaxis microjet therapy is indicated for use on venous and arterial leg ulcers, diabetic foot syndrome, decubitus, infected acute wounds and burn and scald wounds.

Contraindicated for use on malignant tumors, open injuries to blood vessels and unprotected blood vessels, eyes, ears, nose, delicate vessels and structures (e.g., neurovascular structures), complex or highly contaminated wounds or on patients with HIV, hepatitis C or other contagious diseases.

In cases of excessive bleeding and pain, it is the physician's responsibility to decide whether to continue microfluid jet therapy and under what circumstances (e.g., the use of analgesic, decreased intensity of therapy, etc.).